Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) is expected to be posting its quarterly earnings results before the market opens on Wednesday, February 5th. Analysts expect Anavex Life Sciences to post earnings of ($0.17) per share for the quarter. Investors that are interested in participating in the company's conference call can do so using this link.
Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last posted its quarterly earnings data on Monday, December 23rd. The biotechnology company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.03.
Anavex Life Sciences Trading Down 2.8 %
Shares of Anavex Life Sciences stock traded down $0.25 during trading on Thursday, reaching $8.69. The company's stock had a trading volume of 929,989 shares, compared to its average volume of 1,710,958. The company has a 50-day moving average price of $9.97 and a two-hundred day moving average price of $7.63. Anavex Life Sciences has a fifty-two week low of $3.25 and a fifty-two week high of $14.44. The firm has a market cap of $737.05 million, a PE ratio of -16.71 and a beta of 0.69.
Wall Street Analysts Forecast Growth
A number of research firms have commented on AVXL. HC Wainwright restated a "buy" rating and issued a $42.00 price objective on shares of Anavex Life Sciences in a research note on Tuesday, January 28th. D. Boral Capital reissued a "buy" rating and set a $46.00 price target on shares of Anavex Life Sciences in a report on Tuesday, January 28th.
View Our Latest Stock Analysis on AVXL
Anavex Life Sciences Company Profile
(
Get Free Report)
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.
Featured Stories
Before you consider Anavex Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Anavex Life Sciences wasn't on the list.
While Anavex Life Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
